News Lilly joins CGRP race to cure migraine Eli Lilly are gearing up to announce details from the latest Emgality analysis, which can potentially push the biotech to the leading pack of the migraine cure race, among Allergan, Amgen a
News Novartis/Amgen's migraine drug hits market at lower than exp... The FDA has approved the first in a new class of migraine drugs, Novartis and Amgen’s Aimovig, and at a lower than expected list price of $6,900.
News Lilly and Alder showcase latest migraine drug data Lilly and Alder take on the might of Novartis and Amgen
News Novartis/Amgen migraine jab works in tough-to-treat patients Novartis continues to build the case for its Aimovig migraine injection,with data showing it works in a tough-to-treat patient group.
News Sosei see Teva pipeline cull as an opportunity Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.
Oncology CAR-T therapies: Faster, better, cheaper In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends